Meta signed agreements with three nuclear energy companies to help power its artificial intelligence-focused data centers.

ATLANTA, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) complied with federal securities laws. On January 9, 2026, Aquestive disclosed that it received a notice from the FDA that it “had identified deficiencies in the New Drug Application (NDA) submitted by the Company for its product candidate, Anaphylm™ (epinephrine) Sublingual Film, for the treatment of severe allergic reactions, including anaphylaxis, that preclude discussion of labeling and post-marketing commitments for Anaphylm.” Following this news, the price of the Company's stock dropped.

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Capital Link is hosting a series of online Company Presentations, during which the Senior Management teams of leading publicly listed maritime companies will present their business development, strategy, growth prospects, and overall sector outlook. On Wednesday, January 14, 2026, at 10:00 AM ET, Scorpio Tankers Inc. (NYSE: STNG) will kick off Capital Link's 2026 Virtual Corporate Presentation Series, which will continue in the weeks that follow with presentations by senior management teams from additional leading publicly listed maritime companies.

Intel's stock hit its highest point in nearly two years Friday, thanks to a social media post.

San Diego, California--(Newsfile Corp. - January 9, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Klarna Group plc (NYSE: KLAR) securities pursuant and/or traceable to Klarna's offering documents issued in connection with Klarna's September 10, 2025 initial public offering (the "IPO"), have until February 20, 2026 to seek appointment as lead plaintiff of the Klarna class action lawsuit. Captioned Nayak v.

The holiday season added muscle to Apple's (AAPL) iPhone 17 sales. @LikeFolio's data shows strong demand in the tail-end of 2025, something Megan Brantley believes offers a good set-up for 2026.

CANTON, Ga., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced the release of two new home designs at Aurora Ridge at Great Sky, a premier community by Toll Brothers in the scenic hills of Cherokee County, Georgia.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 12, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN) securities between October 22, 2024 and October 28, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON STRIDE, INC. (LRN), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD.

Olin Corporation remains a "Buy" as shares trade at a compressed ~9x mid-cycle earnings, despite recent operational setbacks. The Q4 EBITDA miss is primarily due to one-time maintenance overruns at Freeport; operations have since normalized, but capex may need to rise to sustainable levels. Demand headwinds persist, especially from weak Chinese and U.S. construction, with 2026 results expected to be flat or slightly lower versus 2025.

Realty Income offers a highly diversified, resilient tenant portfolio across 92 industries, limiting exposure to any single client or sector. O maintains a 5.6% yield with a strong history of monthly dividend growth, supported by robust AFFO and FFO performance. Valuation models indicate O's fair value is $63–$71.5 per share, implying 11%–25% upside from current levels.

EEFT's transaction growth, global expansion, acquisitions and digital payment push support its long-term outlook despite recent share declines.

V's tokenization push is evolving beyond security, boosting transaction efficiency, AI-driven insights and seamless payments across devices.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Varonis Systems, Inc. (“Varonis” or the “Company”) (NASDAQ: VRNS) common stock between February 4, 2025 and October 28, 2025, inclusive (the “Class Period”). Varonis investors have until March 9, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON.

NASHVILLE, Tenn.--(BUSINESS WIRE)--The spirit of Music City was on full display on New Year's Eve as indie music venue Anzie Blue and Honda Powersports partnered to present Anzie Blue New Year's Eve Live, a first-time musical event featuring a genre-spanning lineup that was seen worldwide. The six-hour event was livestreamed on CNN.com, with select performances airing live on CNN as part of its daytime coverage of New Year's Eve from cities around the world. Hosted by CNN anchor Lynda Kinkade,.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 12, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Freeport-McMoran Inc. (“Freeport” or the “Company”) (NYSE: FCX) securities between February 15, 2022 and September 24, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON FREEPORT-MCMORAN INC. (FCX), CLICK HERE TO PARTICIPATE I.

New York, New York, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oak Hill Advisors (“OHA”) served as Administrative Agent and Lead Left Arranger for a private unitranche financing supporting Majesco's acquisition of Vitech Systems Group (“Vitech”) and a concurrent refinancing. Majesco, a portfolio company of Thoma Bravo, is a leading provider of cloud-native, AI-native software for insurers in the property and casualty (P&C) and life, annuity and health (L&AH) sectors. Vitech is a complementary provider of cloud-native pension and benefits administration software.

Jazz Pharmaceuticals plc is deeply undervalued, trading at 2.4x sales, as the market overlooks its oncology pivot and robust growth catalysts. Ziihera's Phase 3 data surpassing Herceptin signals a transformative 'pipeline in a product' opportunity, targeting multi-billion-dollar HER2+ cancer market. Zepzelca's expanded front-line SCLC approval and Epidiolex's blockbuster trajectory underpin near-term revenue growth and portfolio diversification.

USAR crosses its 50-day SMA as shares climb 52% in six months, with Stillwater magnet plant advances and a $400M cash boost driving momentum.

PGY hit a 2025 inflection point with three straight GAAP profits, shrinking credit losses and a 125% share surge amid stronger fundamentals.

RPM International posts a Q2 earnings and sales miss as costs pressure margins, though acquisitions lift revenues and management sees improvement ahead.